FENNEC PHARMACEUTICALS INC's ticker is FENC and the CUSIP is 31447P100. A total of 55 filers reported holding FENNEC PHARMACEUTICALS INC in Q1 2023. The put-call ratio across all filers is 0.27 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $26 | -18.8% | 3,460 | -4.8% | 0.00% | – |
| Q2 2023 | $32 | -60.5% | 3,635 | -62.5% | 0.00% | – |
| Q1 2023 | $81 | -9.0% | 9,697 | +4.7% | 0.00% | – |
| Q4 2022 | $89 | -99.6% | 9,260 | +249.7% | 0.00% | – |
| Q3 2021 | $25,000 | +19.0% | 2,648 | -11.6% | 0.00% | – |
| Q2 2021 | $21,000 | -81.4% | 2,994 | -83.5% | 0.00% | – |
| Q1 2021 | $113,000 | +113.2% | 18,194 | +159.0% | 0.00% | – |
| Q4 2020 | $53,000 | -11.7% | 7,024 | -28.3% | 0.00% | – |
| Q3 2020 | $60,000 | -40.0% | 9,803 | -18.1% | 0.00% | – |
| Q2 2020 | $100,000 | +4900.0% | 11,965 | +2103.5% | 0.00% | – |
| Q2 2019 | $2,000 | -88.2% | 543 | -84.1% | 0.00% | – |
| Q1 2019 | $17,000 | -55.3% | 3,416 | -26.2% | 0.00% | – |
| Q3 2018 | $38,000 | +375.0% | 4,631 | +458.0% | 0.00% | – |
| Q2 2018 | $8,000 | – | 830 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Solas Capital Management, LLC | 867,857 | $6,327,000 | 4.44% |
| Sonic Fund II, L.P. | 2,433,230 | $17,738,000 | 1.31% |
| DG Capital Management, LLC | 588,773 | $4,292,000 | 0.93% |
| Southpoint Capital Advisors LP | 4,077,214 | $29,723,000 | 0.52% |
| HARBERT FUND ADVISORS, INC. | 120,851 | $881,000 | 0.49% |
| 683 Capital Management, LLC | 1,110,000 | $8,091,000 | 0.28% |
| Avoro Capital Advisors LLC | 1,670,000 | $12,174,000 | 0.21% |
| VALLEY FORGE INVESTMENT CONSULTANTS INC ADV | 40,000 | $292,000 | 0.16% |
| Tibra Equities Europe Ltd | 46,300 | $338,000 | 0.10% |
| GSA CAPITAL PARTNERS LLP | 68,724 | $501,000 | 0.06% |